CMT4B3

SBF1 | 2013

Illustration of a DNA double helix overlaid on nerve cells, with text reading ‘Experts in CMT: CMT Genes and Subtypes Database

CMT4B3 is caused by mutations in the SBF1 gene. This gene provides instructions for producing SET binding factor 1, a protein involved in phosphoinositide regulation that plays an important role in maintaining normal myelin structure in peripheral nerves. Mutations in the SBF1 gene disrupt Schwann cell function and impair peripheral nerve myelin maintenance, leading to slowed nerve signal transmission

CMT4B3 is autosomal recessive, meaning that both of the gene’s copies must have a CMT-causing mutation to cause this subtype.

Clinical Features

Symptom onset in CMT4B3 is variable from early childhood to early adulthood, beginning in the lower limbs and progressing to the upper body. Patients typically become wheelchair dependent by their mid-30s. Nerve conduction studies show slowed conduction velocities and somewhat reduced amplitudes, consistent with a demyelinating form of CMT. Position and vibratory senses in CMT4B3 are typically more impaired than pain and temperature sensation.

CMT4B1 symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • A steppage-style walking pattern
  • Reduced sensation
  • Reduced or absent reflexes
  • Foot deformities, including high arches and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Kyphoscoliosis (kyphosis + scoliosis)
  • Balance difficulties
  • Additional symptoms not listed here

Disease Course

CMT4B3 shows wide variability in severity and progression. Some individuals remain mildly affected, while others are more severely affected. Progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT4B3

Classification
CMT4

Neuropathy Type
Demyelinating

Inheritance Pattern
Autosomal Recessive

Genetic Context

HGNC-Approved Gene Symbol
SBF1

Gene Full Name
SET Binding Factor 1

HGNC Gene Alias(es)
MTMR5, DENND7A

Chromosome
22q13.33

Zygosity of Responsible Variant
Homozygous or Compound Heterozygous

Mitochondrial Involvement
No

ClinVar Pathogenic Variants

View CMT4B3 ClinVar Variants

More Info

Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

SET Binding Factor 1 (SBF1) Mutation Causes Charcot-Marie-Tooth Disease Type 4B3

Authors

Nakhro, K., Park, J. M., Hong, Y. B., Park, J. H., Nam, S. H., Yoon, B. R., Yoo, J. H., Koo, H., Jung, S. C., Kim, H. L., Kim, J. Y., Choi, K. G., Choi, B. O., & Chung, K. W.

Publication Date
June 7, 2013

Updated: February 22, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.